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Abstract
Background-: Endothelial cell dysfunction may be implicated in the development of multiple organ
failure (MOF) by a number of mechanisms. Among these, altered fibrinolysis promotes fibrin
deposition, which may create microvascular alterations during inflammation. Elevated
concentrations of C-reactive protein (CRP), especially when these persist over time, are correlated
with an increased risk of MOF and death. CRP may inhibit fibrinolysis by inducing plasminogen
activator inhibitor-1 (PAI-1) release from human aortic endothelial cells. Moreover, the
administration of recombinant CRP in volunteers may increase circulating PAI-1 levels.
In this study, we tested the hypothesis that CRP is associated with hypofibrinolysis in intensive care
patients with and without sepsis.
Methods-: We studied the association of inflammation and abnormal fibrinolysis in intensive care
unit (ICU) patients with (n = 11) and without (n = 21) sepsis. The inflammatory response was
assessed by serum concentration of C-reactive protein (CRP), a marker of the acute phase
reaction, which increase rapidly in the inflammatory response, and the plasma fibrinolytic capacity
was evaluated by the Euglobulin Clot Lysis Time (ECLT), determined by a new semi-automatic
method.
Results-: ECLT was significantly higher in septic than non-septic patients (1104 ± 439 vs 665 ± 275
min; p = 0.002) and was significantly correlated with CRP concentration (R2 = 0.45; p < 0.001). In
a multivariate analysis, CRP was the strongest predictor of ECLT (R2 = 0.51, F = 25.6, p < 0.001).
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In addition, the overall ICU length of stay was significantly correlated with CRP (R2 = 0.264, p =
0.003) and ECLT (R2 = 0.259, p = 0.003).
Conclusion-: In critically ill patients a significant correlation thus exists between plasma fibrinolytic
capacity and serum CRP levels. Our data were obtained in the first 24 hours of ICU admission or
of sepsis, thus, the relation between CRP and hypofibrinolysis appeared very quickly. This finding
is compatible with a link between inflammation and abnormal fibrinolysis, and may explain the
negative prognostic value of CRP in critically ill patients.
Background
Endothelial cells have a key role in the control of vascular
permeability and vessel tone, coagulation and fibrinoly-
sis, and inflammatory response [1]. There is an increasing
body of evidence supporting the critical role of the vascu-
lar endothelium in the pathogenesis of multiple organ
failure (MOF) in critically ill patients [2].
Endothelial dysfunction/or activation is associated with
an imbalance in hemostatic functions. Endothelial cells
are responsible for the release of tissue plasminogen acti-
vator (t-PA) and contribute to the release of plasminogen
activator inhibitor-1 (PAI-1). Inhibition of the fibrinolytic
system amplifies the pathogenic role of fibrin deposition
during severe inflammation [3]. Multiple factors, includ-
ing lipoproteins, cytokines, and inflammatory proteins
can modulate the endothelial cells to produce t-PA and
PAI-1 [4].
In infected patients, elevated concentrations of serum
CRP are correlated with a risk of MOF and death [5], espe-
cially when these persist over time [5]. However, the pos-
sible biological involvement of CRP in the development
of MOF and death is unknown.
CRP can act directly on endothelial cells, inducing, for
example, the expression of intercellular adhesion mole-
cule (ICAM)-1 [6] and the production of inflammatory
cytokines such as interleukin- (IL)-6 [7]. It may also
inhibit fibrinolysis by inducing PAI-1 release from human
aortic endothelial cells [8]. Moreover, the administration
of recombinant CRP in volunteers may increase circulat-
ing PAI-1 levels [9].
In this study, we tested the hypothesis that CRP is associ-
ated with hypofibrinolysis as measured by ECLT in inten-
sive care patients with and without sepsis.
Material and methods
Subjects
After approval by the A. Vésale hospital ethics committee,
we studied 32 ICU patients with severe sepsis (n = 11) or
other diagnoses (n = 21). Infection definition required
isolation of a microorganism from a normally sterile body
site, concurrent with accompanying signs and symptoms
of sepsis and decision of antibiotic therapy. Criteria for
severe sepsis included signs of at least one organ dysfunc-
tion attributed to sepsis [10]. All patients (septic and non-
septic) were enrolled in the first day of ICU admission to
limit the delay of inflammatory response. The exclusion
criteria were: antibiotics treatment in the non-septic group
except for surgical prophylaxis, red blood cell transfusion
in the last 72 h, active hemorrhage, hematological disor-
ders, recent cytotoxic chemotherapy, burns, cardiogenic
shock, cirrhosis, pregnancy. The simplified acute physio-
logic score (SAPS II score) [11] was determined in each
patient during the first 24 hours after admission.
Blood samples
Blood samples were obtained during the first 24 hours of
sepsis or on the first day of admission for non-septic
patients. Serum samples were collected in vacuum tubes
without anticoagulant. Plasma samples were harvested in
citrated vacuum tubes and put in melting ice. Whole
blood was collected on EDTA-treated tubes. CRP was eval-
uated by antibody-binding and turbidity measurement on
SYNCHRON LX®. Fibrinogen was determined by
thrombin time on a STA® automate (STAGO). Leukocyte
and platelet counts were determined on a hemocytometer
(CELL-DYN4000®, ABBOTT). All tests were performed on
blood obtained from the same venipuncture.
Plasma fibrinolytic capacity
The Euglobulin Clot Lysis Time (ECLT), which is the most
common test used to estimate the plasma fibrinolytic
capacity, represents the balance between t-PA and PAI-1
activities [12]. ECLT was measured on fresh plasma the
same day as other parameters by a method described else-
where [13]. Briefly, we designed a completely computer-
ized, semi-automatic, 8-channel device for measurement
and determination of fibrin clot lysis (Lysis Timer, EREM,
Belgium). The lysis time is evaluated by a mathematical
analysis of the lysis curve and the results are expressed in
minutes (range: 5 to 9999). The efficiency scores of the
method are <4% in intra-assay and <7% in inter-assay.
Statistics
We used SigmaStat® software package (Jandle Scientific).
The data are presented as mean ± SD. Correlation between
variables was analyzed using a Pearson correlation test. AThrombosis Journal 2004, 2:7 http://www.thrombosisjournal.com/content/2/1/7
Page 3 of 5
(page number not for citation purposes)
multivariate analysis was used with stepwise backward
selection of the explicative variables. Sepsis was consid-
ered as a dichotomous variable while all other data were
considered as continuous (CRP, fibrinogen, leukocyte,
monocyte and platelet counts). ECLT was the dependent
variable. A probability level of p < 0.05 was considered as
statistically significant.
Results
The major cause of severe sepsis (9 patients) or septic
shock (2 patients) was pneumonia (8 patients); angio-
cholitis was the cause in 1 patient, and in 2 patients the
cause was not identified. In 8 patients (7 with pneumonia
and 1 with angiocholitis), the infection was due to a Gram
negative bacteria. Only 1 patient had documented bacter-
emia. Non-septic patients were admitted for postoperative
surveillance (7 patients), intracerebral hemorrhage (3
patients), heart failure (3 patients), drug intoxication (3
patients), or aggravated chronic obstructive pulmonary
disease (5 patients).
As expected, inflammatory parameters such as white
blood cells and CRP levels, the SAPS II score and ECLT
were higher in the septic than the non-septic population
(Table 1). In an univariate analysis (in all patients), the
ECLT was strongly correlated with serum CRP concentra-
tions (R2 = 0.45; p < 0.001) with no perceptible threshold
(Fig 1). Surprisingly, there was no relationship between
the SAPS score and ECLT (R2 = 0.08; p = 0.15). In multi-
variate analysis, ECLT was best predicted by the CRP level
(R2 = 0.51; F = 25.6; p < 0.001) and not significantly by
sepsis or the fibrinogen concentration. Interestingly, the
ICU length of stay was significantly correlated with CRP
(R2 = 0.264, p = 0.003) and ECLT (R2 = 0.259, p = 0.003)
in all patients, and in the survivors (R2 = 0.13, p = 0.05
and R2 = 0.3, p = 0.003, respectively).
Discussion
Many studies have demonstrated that sepsis is associated
with endothelial cell dysfunction and promotes coagula-
tion activation [14]. Although levels of t-PA antigen
increase in sepsis, fibrinolysis is inhibited by increased
levels of PAI-1. ECLT is, therefore, an interesting test,
because it represents the balance between t-PA and PAI-1
activities. Previously considered as an imprecise method,
we have been able to improve the precision and reproduc-
ibility of the test with a new semi-automatic device [13].
Correlation between serum CRP levels and Euglobulin Clot Lysis Time Figure 1
Correlation between serum CRP levels and Euglobulin Clot Lysis Time.Thrombosis Journal 2004, 2:7 http://www.thrombosisjournal.com/content/2/1/7
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Inhibition of the fibrinolytic system may contribute to
MOF, as fibrin can activate endothelial cells leading to a
disorganization of the monolayer and the release of
inflammatory cytokines [4]. Increased CRP levels are asso-
ciated with worse outcomes and MOF in ICU patients [3].
The role of CRP on fibrinolysis is unknown in vivo. Our
data suggest that CRP could itself be involved in the proc-
esses leading to endothelium dysfunction. The observed
relationship does not prove a direct biological link
between increasing CRP and hypofibrinolysis; however,
indirect arguments exist in support of the concept.
Several in vitro studies have reported the direct effects of
CRP on endothelial cells [6-8]. In vivo, Cleland et al. [15]
reported a relationship between serum CRP levels and the
forearm blood flow response to NG-monomethyl-L-
arginine (L-NMMA), reflecting endothelial dysfunction.
Bisoendial et al. reported that the administration of CRP
in volunteers impairs the fibrinolytic balance [9]. In addi-
tion, CRP has a strong prognostic value in acute coronary
syndromes [16]. In a non-selected population with no
inflammatory syndrome (CRP below 1.5 mg/dl, n = 160),
we also observed that ECLT was significantly correlated
with serum CRP levels [17].
CRP could also act indirectly on endothelial cells via the
action of monocytes and the release of tumor necrosis fac-
tor-α (TNF-α). TNF-α is a strong inducer of PAI-1 produc-
tion  in-vitro  and  in-vivo. This mechanism seems to be
important in sepsis, as high plasma levels of PAI-1 are
associated with poor outcome [18]. Moreover, an associa-
tion between CRP and TNF-α has also been described
[19]. CRP can induce the monocyte release of cytokines
such as IL-1β, IL-6, and also TNF-α through Fc receptors
(γRI/CD64, FcγRIIa/CD32) [20].
CRP also has essential biological functions. No polymor-
phism of either the gene coding sequence or of the protein
itself has been described in humans [21]. Also, high levels
of human CRP protect against lethal infection. Transgenic
mice capable of produce human CRP are protected against
lethal infection by Gram positive and negative bacteria,
Szalai et al [22,23].
This work is a pilot study. We have chosen to include
patients in the first day of ICU admission to limit the pos-
sible rapid effect of inflammatory response on fibrinoly-
sis, especially in septic patients. Indeed, this particular
patient population has inflammatory reaction before
signs of severe sepsis and thus before their admission to
ICU. In fact, we have studied ECLT test at the onset of the
organ dysfunction and the inflammatory reaction. Other
studies with serial measurement of ECLT in patients who
developed nosocomial ICU infections are needed to study
the time course of these events. Moreover, we could not
definitively exclude that all patients in the non-septic
groups were non infected. For example, some non-septic
patients with decompensated COPD may have minor
infections, despite the negative microbiology cultures and
the absence of antibiotic therapy. Viral infections were
also possible in some patients.
Moreover, it would be of great interest to determine the
interactions between CRP and ECLT with IL-6, TNF-α and
endothelium dysfunction markers such as soluble throm-
bomodulin and soluble von Willebrand factor.
Conclusion
Despite accumulating evidence that the inflammatory and
coagulation systems are activated in sepsis, little is known
about the mechanisms that ultimately lead to organ dys-
function and death. Our data were obtained in the first 24
hours of ICU admission or of sepsis, thus, the relation
between CRP and hypofibrinolysis appeared very quickly.
Prospective studies including the time course of CRP and
hypofibrinolysis would provide additional information
about this relationship.
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Table 1: Population characteristics
Sepsis (n = 11) Non-sepsis (n = 21) p value
Age, years 68 ± 19 67 ± 17 0.95
SAPS II 47 ± 11 25 ± 14 0.001
ICU stay, days 11.6 ± 7.8 6.7 ± 6.8 0.07
Death, n (%) 2 (18) 3 (14) 0.57
Leukocytes 
(×103 cells/µl)
10.4 ± 4.5 10.9 ± 3.7 0.74
Monocytes 
(×103 cells/µl)
549 ± 225 711 ± 398 0.24
Platelets (×103 
cells/µl)
207 ± 157 234 ± 94 0.54
Fibrinogen 
(mg/dl)
657 ± 123 445 ± 132 <0.001
CRP (mg/dl) 24.2 ± 10.5 7.6 ± 6.1 <0.001
ECLT (min) 1104 ± 439 665 ± 275 0.002
Mean ± SD; p value (t-stest).
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